PL3277683T3 - Trójpierścieniowe pochodne 1-(cyklo)alkilopirydyn-2-onu użyteczne w leczeniu raka - Google Patents

Trójpierścieniowe pochodne 1-(cyklo)alkilopirydyn-2-onu użyteczne w leczeniu raka

Info

Publication number
PL3277683T3
PL3277683T3 PL16723536T PL16723536T PL3277683T3 PL 3277683 T3 PL3277683 T3 PL 3277683T3 PL 16723536 T PL16723536 T PL 16723536T PL 16723536 T PL16723536 T PL 16723536T PL 3277683 T3 PL3277683 T3 PL 3277683T3
Authority
PL
Poland
Prior art keywords
cyclo
cancer
useful
treatment
tricyclic fused
Prior art date
Application number
PL16723536T
Other languages
English (en)
Polish (pl)
Inventor
Saravanan VADIVELU
Sridharan Rajagopal
Murugan CHINNAPATTU
Pavan Kumar GONDRALA
Dhanalakshmi SIVANANDHAN
Chandrika MULAKALA
Original Assignee
Jubilant Biosys Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jubilant Biosys Limited filed Critical Jubilant Biosys Limited
Publication of PL3277683T3 publication Critical patent/PL3277683T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL16723536T 2015-03-30 2016-03-30 Trójpierścieniowe pochodne 1-(cyklo)alkilopirydyn-2-onu użyteczne w leczeniu raka PL3277683T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1636CH2015 2015-03-30
PCT/IN2016/050098 WO2016157221A1 (en) 2015-03-30 2016-03-30 Tricyclic fused derivatives of 1-(cyclo)alkyl pyridin-2-one useful for the treatment of cancer
EP16723536.5A EP3277683B1 (en) 2015-03-30 2016-03-30 Tricyclic fused derivatives of 1-(cyclo)alkyl pyridin-2-one useful for the treatment of cancer

Publications (1)

Publication Number Publication Date
PL3277683T3 true PL3277683T3 (pl) 2022-05-23

Family

ID=56015058

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16723536T PL3277683T3 (pl) 2015-03-30 2016-03-30 Trójpierścieniowe pochodne 1-(cyklo)alkilopirydyn-2-onu użyteczne w leczeniu raka

Country Status (16)

Country Link
US (2) US10689390B2 (https=)
EP (1) EP3277683B1 (https=)
JP (1) JP6764877B2 (https=)
KR (1) KR102588109B1 (https=)
CN (1) CN107548393B (https=)
AU (1) AU2016242473B2 (https=)
BR (1) BR112017020739B1 (https=)
CA (1) CA2980266C (https=)
DK (1) DK3277683T3 (https=)
ES (1) ES2911886T3 (https=)
IL (1) IL254528B (https=)
MX (1) MX376112B (https=)
PL (1) PL3277683T3 (https=)
PT (1) PT3277683T (https=)
RU (1) RU2721120C2 (https=)
WO (1) WO2016157221A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202100277T1 (it) * 2015-09-09 2021-07-12 Jubilant Biosys Ltd Derivati triciclici fusi di piridina-2-0ne e loro uso come inibitori di brd4
CA3045855A1 (en) * 2016-11-10 2018-05-17 Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. Nitrogenous macrocyclic compound, preparation method therefor, pharmaceutical composition and application thereof
WO2019214399A1 (zh) * 2018-05-10 2019-11-14 罗欣药业(上海)有限公司 苯并七元杂环类化合物、其制备方法、药物组合物及应用
CN110172068A (zh) * 2019-06-05 2019-08-27 河南龙湖生物技术有限公司 具有抗肿瘤活性的苯并噻唑类化合物及其制备方法和应用
US12527741B2 (en) 2021-06-17 2026-01-20 Wisconsin Alumni Research Foundation Modular dendron micelles for treatment of pulmonary diseases related to fibrosis and viral infection including COVID-19

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1545767A (en) * 1976-06-30 1979-05-16 Aspro Nicholas Ltd Isoquinoline derivatives
WO2008133288A1 (ja) 2007-04-25 2008-11-06 Daiichi Sankyo Company, Limited 三環性アリール化合物
ES2480994T3 (es) 2008-03-31 2014-07-29 Genentech, Inc. Compuestos de tipo benzopirano y benzoxepina inhibidores de PI3K y métodos de uso
US9085582B2 (en) 2010-06-22 2015-07-21 Glaxosmithkline Llc Benzotriazolodiazepine compounds inhibitors of bromodomains
AR084070A1 (es) * 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
CA2901352A1 (en) * 2013-02-19 2014-08-28 Bayer Pharma Aktiengesellschaft Bicyclo 2,3-benzodiazepines and spirocyclically substituted 2,3-benzodiazepines
WO2014139324A1 (en) * 2013-03-12 2014-09-18 Abbvie Inc. Tetracyclic bromodomain inhibitors
WO2015018520A1 (en) 2013-08-06 2015-02-12 Oncoethix Sa A bet-brd inhibitor represents a novel agent for alk positive anaplastic large cell lymphoma
US9814728B2 (en) * 2013-09-20 2017-11-14 Saint Louis University Inhibition of DUX4 expression using bromodomain and extra-terminal domain protein inhibitors (BETi)

Also Published As

Publication number Publication date
EP3277683B1 (en) 2022-03-09
JP2018510203A (ja) 2018-04-12
NZ735972A (en) 2024-08-30
KR102588109B1 (ko) 2023-10-12
AU2016242473A1 (en) 2017-10-26
DK3277683T3 (en) 2022-05-02
CN107548393A (zh) 2018-01-05
US11319326B2 (en) 2022-05-03
RU2017135205A (ru) 2019-04-10
BR112017020739A2 (pt) 2018-07-17
PT3277683T (pt) 2022-06-28
CN107548393B (zh) 2021-03-02
MX376112B (es) 2025-03-07
IL254528B (en) 2020-11-30
EP3277683A1 (en) 2018-02-07
IL254528A0 (en) 2017-11-30
RU2017135205A3 (https=) 2019-07-17
RU2721120C2 (ru) 2020-05-15
BR112017020739B1 (pt) 2023-03-14
US20200331926A1 (en) 2020-10-22
ES2911886T3 (es) 2022-05-23
US20180282345A1 (en) 2018-10-04
CA2980266A1 (en) 2016-10-06
JP6764877B2 (ja) 2020-10-07
US10689390B2 (en) 2020-06-23
AU2016242473B2 (en) 2020-06-25
HK1248686A1 (zh) 2018-10-19
MX2017012387A (es) 2018-06-11
KR20170132278A (ko) 2017-12-01
WO2016157221A1 (en) 2016-10-06
CA2980266C (en) 2025-05-06

Similar Documents

Publication Publication Date Title
IL268737A (en) Processes for the preparation of benzodiapine derivatives
IL258154A (en) Pyrazolopyrimidine history as btk inhibitors for cancer treatment
IL246140B (en) History of bicyclic heterocyclics as bromodomain repressors
IL259281B (en) History of bipyrazolyl used in the treatment of autoimmune diseases
HUE041751T2 (hu) Rákfajták kezeléséhez felhasználható fuzionált biciklusos (hetero)aromás vegyületek
IL286788A (en) Methods for the preparation of cytotoxic benzodiazepine compounds
SI3353177T1 (sl) Triciklični heterocikli za zdravljenje raka
HUE056357T2 (hu) Szobetirom származékok
EP3135674A4 (en) Novel bicyclic or tricyclic heterocyclic compound
IL254528B (en) Fused tricyclic derivatives of 1-(cyclo)alkylpyridine-2-one are useful for cancer treatment
IL247808A (en) History of splosporin for the treatment of cancer
ZA201606921B (en) Use of xanthophylls for the treatment of cancers
IL267305A (en) Process for the manufacture of diazepine derivatives
PL3221297T3 (pl) Sposób syntezy pochodnych benzazepiny